Valuation: Healios K.K.

Market Cap 33.35B 211M 183M 171M 157M 295M 20.12B 299M 2B 787M 10.09B 794M 777M P/E 2026 *
-6.78x
P/E 2027 * -12x
Enterprise Value 33.09B 210M 181M 169M 155M 292M 19.97B 297M 1.99B 780M 10.01B 788M 771M EV / Sales 2026 *
54.9x
EV / Sales 2027 * 3.82x
Free-Float
77.9%
Yield 2026 *
-
Yield 2027 * -
07-27 Healios Announces Selection of Akt-01/Hlcn061 Commercial Manufacturing Process for Amed Project CI
04-08 Japan Stocks Rise as US-Iran Ceasefire Eases Geopolitical Concerns MT
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
04-07 Healios to Supply Stem Cell Culture Material to JENECELL in Cosmetics Deal MT
04-07 Healios K.K. Enters Agreement with Jenecell to Supply Culture Supernatant CI
03-27 Healios K.K. Receives Grant Approval from Ministry of Economy, Trade and Industry for Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities CI
02-20 Healios Plans Capital Reduction to Eliminate Retained Losses MT
02-13 Healios K.K. announced that it has received ¥6.298588125 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
02-03 Healios K.K. Announces Start of ARDS Clinical Trial in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-29 Healios K.K. announced that it expects to receive ¥6.298588125 billion in funding from Athos Capital Limited, New Holland Capital, LLC, Lighthouse Investment Partners, LLC, Walleye Capital LLC CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
01-20 Healios K.K. Announces Submission of Clinical Trial Notification in Japan for the Global Phase 3 REVIVE-ARDS Study CI
01-20 Healios Submits Japan Trial Plan for Global Phase 3 ARDS Study MT
1 day+4.45%
1 week+9.79%
Current month+9.32%
1 month-1.15%
3 months-23.89%
6 months-32.64%
Current year-5.84%
1 week 234
Extreme 234
259
1 month 208
Extreme 208
285
Current year 208
Extreme 208
483
1 year 208
Extreme 208
648
3 years 114
Extreme 114
747
5 years 114
Extreme 114
2,557
10 years 114
Extreme 114
2,557
Manager TitleAgeSince
Chief Executive Officer 49 01/03/2018
Director of Finance/CFO 49 16/07/2019
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 49 01/02/2012
Director/Board Member 49 01/03/2018
Director/Board Member 73 01/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+4.45%+9.79%-59.05%+1.57% 211M
+8.49%+20.55%+70.77%+103.07% 68.12B
-0.63%+5.01%+37.09%+65.95% 55.18B
-1.09%+32.96%+19.67%+509.20% 28.63B
+0.52%+18.87%+55.18%+5.18% 23.99B
+2.72%+3.41%-16.11%-12.04% 23.53B
-0.53%+7.94%+46.78%-22.59% 18.45B
-2.22%+10.63%+30.76%+627.59% 16.44B
-3.88%+16.98%+199.30%+350.94% 15.83B
+3.58%+1.96%+43.35%+162.22% 13.4B
Average +1.15%+10.98%+42.77%+179.11% 26.38B
Weighted average by Cap. +2.02%+13.09%+51.06%+161.91%

Financials

2026 *2027 *
Net sales 602M 3.82M 3.3M 3.08M 2.83M 5.32M 363M 5.41M 36.19M 14.2M 182M 14.34M 14.03M 9.12B 57.82M 50.02M 46.71M 42.85M 80.59M 5.5B 81.87M 548M 215M 2.76B 217M 212M
Net income -4.77B -30.25M -26.17M -24.44M -22.42M -42.17M -2.88B -42.84M -287M -113M -1.44B -114M -111M -2.94B -18.67M -16.15M -15.08M -13.84M -26.03M -1.78B -26.44M -177M -69.46M -891M -70.12M -68.59M
Net Debt -260M -1.65M -1.43M -1.33M -1.22M -2.3M -157M -2.33M -15.61M -6.13M -78.59M -6.19M -6.05M 1.46B 9.28M 8.02M 7.49M 6.87M 12.93M 883M 13.14M 87.92M 34.51M 443M 34.84M 34.07M
Logo Healios K.K.
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Employees
75
Date Price Change Volume
10/08/26 ¥258.00 +4.45% 1,451,000
07/08/26 ¥247.00 +0.41% 1,355,800
06/08/26 ¥246.00 -2.77% 966,100
05/08/26 ¥253.00 +5.42% 1,686,700
04/08/26 ¥240.00 +2.13% 1,062,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
247.00JPY
Average target price
779.83JPY
Spread / Average Target
+215.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4593 Stock